Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
Elanco has launched Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for treating canine allergic and atopic dermatitis. The product offers a differentiated 6 to 8-week dosing interval, compared to the 4 to 8 weeks of the current market incumbent, lokivetmab, and starts controlling itch within 24 hours. Befrena is Elanco's second USDA-approved monoclonal antibody, joining Trutect, and targets the $1.3 billion U.S.
Key figures
- Market size usd
- 1300000000
- Dosing interval weeks
- 6 to 8
- Itch control onset hours
- 24
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.